Business Description
TransCode Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US89357L3033
Description
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.34 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | -189.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 91.42 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.25 | |||||
| 9-Day RSI | 16.77 | |||||
| 14-Day RSI | 23.01 | |||||
| 6-1 Month Momentum % | -62.3 | |||||
| 12-1 Month Momentum % | -94.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | |||||
| Quick Ratio | 1.58 | |||||
| Cash Ratio | 0.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -248.3 | |||||
| Shareholder Yield % | -404.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -547.22 | |||||
| ROA % | -237.32 | |||||
| ROIC % | -1612.79 | |||||
| ROC (Joel Greenblatt) % | -3169.51 | |||||
| ROCE % | -536.63 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.11 | |||||
| Price-to-Tangible-Book | 1.11 | |||||
| EV-to-EBIT | -0.05 | |||||
| EV-to-Forward-EBIT | -0.06 | |||||
| EV-to-EBITDA | -0.05 | |||||
| EV-to-Forward-Revenue | 1 | |||||
| EV-to-FCF | -0.05 | |||||
| Price-to-Net-Current-Asset-Value | 1.39 | |||||
| Earnings Yield (Greenblatt) % | -2000 | |||||
| FCF Yield % | -647.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNAZ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TransCode Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -266.137 | ||
| Beta | 0.6 | ||
| Volatility % | 272.32 | ||
| 14-Day RSI | 23.01 | ||
| 14-Day ATR ($) | 1.184587 | ||
| 20-Day SMA ($) | 7.498835 | ||
| 12-1 Month Momentum % | -94.91 | ||
| 52-Week Range ($) | 3.21 - 263.999985 | ||
| Shares Outstanding (Mil) | 0.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TransCode Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TransCode Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TransCode Therapeutics Inc Frequently Asked Questions
What is TransCode Therapeutics Inc(RNAZ)'s stock price today?
The current price of RNAZ is $3.52. The 52 week high of RNAZ is $264.00 and 52 week low is $3.21.
When is next earnings date of TransCode Therapeutics Inc(RNAZ)?
The next earnings date of TransCode Therapeutics Inc(RNAZ) is .
Does TransCode Therapeutics Inc(RNAZ) pay dividends? If so, how much?
TransCode Therapeutics Inc(RNAZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers